TRIB

Trinity Biotech plc

$5.88

10.08%
SectorHealthcareIndustryMedical DevicesCountryIreland

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.

Source: Yahoo Finance
Q-Score33/ 100
Market Cap$4.8M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.75
AI summary

Price & performance

1M+2.2%
3M-45.3%
YTD-73.8%
1Y-80.2%
52-week range—
Beta0.75
Full chart and returns against a benchmark

Q-Score

33/ 100

Quality against peers; 50 is the peer median.

Growth32
Risk37
Performance36
Valuation36
Profitability44
Leverage40
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2024

Revenue$61.6M+8.3%
Net income-$31.2M
Net margin-50.7%+14.2 pts
Historical fundamentals

Revenue exposure

-19%of revenue from outside the US
United States119%
Ireland34%
Regions, segments, customers and suppliers

Valuation

TRIBIndustryP/E—29.61P/S0.083.49EV/EBITDA—18.38P/B—3.39PEG——
Dividend yield0.00%
Every valuation metric